Watson Pharma says FDA approved generic Toprol XL
Daily Advance - Business (Free subscription) | 08/03/2009
MORRISTOWN, N.J. — Watson Pharmaceuticals Inc. said Monday it received approval for a generic ...
Daily Advance - Business (Free subscription) | 08/03/2009
MORRISTOWN, N.J. — Watson Pharmaceuticals Inc. said Monday it received approval for a generic ...
San Fransisco Chronicle (Free subscription) | 08/03/2009
Watson Pharmaceuticals Inc. said Monday it received approval for a generic version of the high blood pressure and angina drug Toprol XL, and plans to begin shipping the product immediately. Watson said the Food and Drug Administration approval 25 mg and 50 mg... Sponsored Topics: US Food and Drug Administration - Food and Drug Administration - Hypertension - Watson Pharmaceuticals - United States
Market Watch (Free subscription) | 07/29/2009
LONDON (MarketWatch) -- Watson Pharmaceuticals Inc. said Wednesday that its second-quarter net profit fell 12% to $53 million, or 46 cents a share, from $60.3 million, or 53 cents a share, a year earlier, as the group also raised its 2009 outlook. Watson said net revenue in the quarter rose 8.8% to $677.8 million and adjusted earnings were 61 cents a share. Analysts polled by FactSet had been expecting...
Financial24 (Free subscription) | 07/28/2009
July 28 - Watson Pharmaceuticals Inc: Announces license agreement with GeneraMedix for generic version of Ferrlecit ...
Daily Advance - Business (Free subscription) | 07/28/2009
MORRISTOWN, N.J. — Watson Pharmaceuticals Inc. said Monday Chief Financial Officer Mark W. Dur...
Miami Herald (Free subscription) | 07/27/2009
Watson Pharmaceuticals Inc. said Monday Chief Financial Officer Mark W. Durand has taken a leave of absence due to health reasons.
Seattle Times (Free subscription) | 07/27/2009
Watson Pharmaceuticals Inc. said Monday Chief Financial Officer Mark W. Durand has taken a leave of absence due to health reasons.
Market Wire (Free subscription) | 07/16/2009
NEW DELHI, INDIA (MARKET WIRE) Investors seeking the best unbiased research on Mohawk Industries Inc. (NYSE: MHK), Oil States International Inc. (NYSE: OIS), Precision Castparts Corp. (NYSE: PCP), Marvel Entertainment Inc. (NYSE: MVL), IMS Health Inc. (NYSE: RX) and Watson Pharmaceuticals Inc. (NYSE: WPI) should sign up to StreetInvesting.com today to gain free access to the most educational research...
Market Watch (Free subscription) | 07/14/2009
NEW YORK (MarketWatch) -- Watson Pharmaceuticals Inc. said Tuesday that it has received a complete response letter from the U.S. Food and Drug Administration on its new drug application for a 24-week formulation of prostate-cancer treatment Trelstar. The pharmaceutical company said that the FDA has asked for clarification about clinical testing and more information about its chemistry, manufacturing...
Daily Advance - Business (Free subscription) | 06/25/2009
NEW YORK — Watson Pharmaceuticals Inc. said Wednesday it recieved Food and Drug Administration...
Miami Herald (Free subscription) | 06/25/2009
Watson Pharmaceuticals Inc. said Wednesday it recieved Food and Drug Administration approval for a generic version of Duramed Pharmaceuticals' Plan B emergency contraceptive.
Seattle Times (Free subscription) | 06/25/2009
Watson Pharmaceuticals Inc. said Wednesday it recieved Food and Drug Administration approval for a generic version of Duramed Pharmaceuticals' Plan B emergency contraceptive.
San Fransisco Chronicle (Free subscription) | 06/25/2009
Watson Pharmaceuticals Inc. said Wednesday it recieved Food and Drug Administration approval for a generic version of Duramed Pharmaceuticals' Plan B emergency contraceptive. The generic version is approved for prescription use only. Duramed has exclusive... Sponsored Topics: US Food and Drug Administration - Barr Pharmaceuticals - Emergency contraception - Health - United States
EmailWire.Com (Free subscription) | 06/18/2009
(EMAILWIRE.COM, June 18, 2009 ) DALLAS, Texas InvestorSoup.com announces the release of Stock Alerts covering market movers: Watson Pharmaceuticals Inc. (NYSE: WPI), Edison International (NYSE: EIX), The Scotts Miracle-Gro Co. (NYSE: SMG), Silicon Laboratories Inc. (Nasdaq: SLAB) and Alvarion...
Business Pundit (Free subscription) | 06/17/2009
Image: Pharmer.org Watson Pharmaceuticals acquired Arrow Group for $1.75 billion in stock and cash today. The deal is the latest in a wave of pharmaceutical company mergers and acquisitions. Bloomberg has more: Watson Pharmaceuticals Inc. agreed to buy closely held Arrow Group for $1.75 billion in cash and stock, gaining more than 100 generic medicines. Watson, [...]